AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Marti Technologies, Inc.
Video analysis: MRT
All videosNo video analysis for this stock yet. Request one from our team.
News: MRT
Marti Increases Share Repurchase Authorization to $5 Million and Extends Program Through April 2027
ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced that its Board of Directors (the “Board”) has increased the authorization under the Company's share repurchase program (the “Repurchase Program”) from $2.5 million to $5.0 million and extended the Repurchase Program through April 26, 2027.The expanded authorization reflects Marti's continued commitment to disciplined capital allocation and provi.
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with Sjögren's disease (SjD), the second most prevalent rheumatic autoimmune disease1.
Marti's Ride-Hailing Service Reaches 4.90 Million Riders and 584 Thousand Registered Drivers, Exceeding September 30, 2026 Targets a Month Earlier Than Planned
ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, announced today that as of September 2, 2026, Marti's ride-hailing service has reached 4.90 million riders and 584 thousand registered drivers, exceeding the September 30, 2026 targets of 4.90 million riders and 580 thousand registered drivers.Marti's number of ride-hailing riders grew 85% from September 2, 2025 to September 2, 2026. The number of registered.
Marti Technologies: Buy The Inflection Point
Marti Technologies (MRT) delivered a major operating inflection, turning adjusted EBITDA positive and expanding gross margin to 77%, while accelerating revenue growth. I maintain a speculative buy rating with a $3.88 price target, but highlight that convertible debt implies upside should be viewed on a fully diluted basis. Regulatory uncertainty, balance sheet risks, and potential competition threaten margins and limit de-risking despite strong operating momentum and city expansion.
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript
Marti Technologies, Inc. (MRT) Q2 2026 Earnings Call Transcript
Marti Technologies H1 Earnings Call Highlights
Marti Technologies NYSEAMERICAN: MRT reported second-quarter 2026 revenue growth of 141% year over year to nearly $20 million and reached positive adjusted EBITDA for the first time, as its ride-hailing marketplace expanded and costs rose more slowly than revenue.
Marti Achieves Record Second Quarter with 141% Revenue Growth, 77% Gross Profit Margin, Significant Improvement in Profitability, and Increased Guidance
ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today reported a strong second quarter ended June 30, 2026, delivering another quarter of triple-digit revenue growth, expanding gross margin to 77%, achieving positive Adjusted EBITDA for the first time, and increasing its full-year 2026 guidance. The results reflect continued strength in Marti's rapidly growing ride-hailing marketplace, increasing platform m.
